List of Excipients in Branded Drug AMRIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	AMRIX	cyclobenzaprine hydrochloride	16590-596	D&C YELLOW NO. 10
STAT RX USA LLC	AMRIX	cyclobenzaprine hydrochloride	16590-596	DIETHYL PHTHALATE
STAT RX USA LLC	AMRIX	cyclobenzaprine hydrochloride	16590-596	ETHYLCELLULOSES

AMRIX Excipient Strategy and Commercial Opportunities for Cyclobenzaprine Extended-Release Capsules

Last updated: September 24, 2026

AMRIX is an extended-release capsule containing cyclobenzaprine hydrochloride, indicated for acute, painful musculoskeletal spasm. Its commercial value is tied to multiparticulate extended-release technology, dose flexibility, and once-daily administration rather than molecular exclusivity. The main opportunity is a lower-cost generic, an improved modified-release formulation, or a differentiated product with better tolerability and adherence. The principal technical risk is reproducing AMRIX’s release profile while maintaining bioequivalence across fed and fasted conditions.

What is AMRIX and how is it formulated?

AMRIX is a 15 mg and 30 mg extended-release capsule administered once daily. The reference product uses cyclobenzaprine hydrochloride in a multiparticulate delivery system intended to control drug release over approximately 24 hours. The product is not an immediate-release tablet with a simple polymer matrix. Its performance depends on drug-loaded particles, coating structure, capsule fill, and excipient interactions.

Attribute	AMRIX reference product
Active ingredient	Cyclobenzaprine hydrochloride
Dosage form	Extended-release capsule
Strengths	15 mg and 30 mg
Route	Oral
FDA approval	2007
Reference NDA	NDA 021777
Original sponsor	Cephalon
Later commercial owner	Teva Pharmaceuticals
Indication	Acute, painful musculoskeletal conditions
Dosing	Once daily
Regulatory pathway for copies	ANDA, subject to FDA bioequivalence requirements

The product label identifies conventional capsule and pellet-processing excipients, including lactose monohydrate, microcrystalline cellulose, hypromellose, povidone, magnesium stearate, talc, sodium lauryl sulfate, titanium dioxide, gelatin, and colorants. Exact excipient use can vary by strength and manufacturing site, so the approved labeling and current FDA product records control the commercial assessment. (FDA, 2017a; DailyMed, 2023)

What excipient strategy supports an AMRIX generic?

A successful generic strategy should treat excipients as part of the release-control architecture rather than as interchangeable fillers. The most relevant excipient functions are:

Functional role	Likely excipient classes	Commercial and technical purpose
Pellet core formation	Microcrystalline cellulose, lactose, povidone	Provides mechanical strength and drug uniformity
Binder control	Povidone or equivalent polymeric binder	Controls granule or pellet integrity
Release coating	Hypromellose and other film-forming polymers	Regulates hydration and drug diffusion
Coating process aid	Talc, surfactants, plasticizers	Reduces sticking and improves coating uniformity
Lubrication	Magnesium stearate	Supports capsule filling and equipment performance
Wetting	Sodium lauryl sulfate or another surfactant	Improves wetting of hydrophobic drug particles
Capsule shell	Gelatin or hypromellose	Provides dosage-form enclosure
Appearance	Titanium dioxide and approved colorants	Supports product identification and branding

How should the release-control system be designed?

The central formulation choice is whether to replicate a coated-pellet architecture or develop an alternative system, such as:

1. Drug-layered inert cores with polymeric overcoating.
2. Matrix pellets using hydrophilic polymers.
3. Mini-tablets filled into hard capsules.
4. Multiple populations of pellets with different coating weights.
5. A dual-release system combining immediate and delayed fractions.

A coated-pellet system is likely to offer the lowest regulatory risk when the reference product has a multiparticulate structure. It permits adjustment of release by varying polymer type, coating weight gain, pore-former concentration, particle-size distribution, and pellet population.

The formulation should be screened against pH, agitation, ionic strength, and ethanol exposure. Cyclobenzaprine is a basic compound, and pH-dependent solubility can affect release. Surfactant concentration and lubricant level can also change wetting and dissolution. These factors can create bioequivalence failures even when the nominal polymer composition is similar.

Which excipients create the greatest development risk?

Hypromellose and other release-controlling polymers are the highest-impact excipients. Differences in viscosity grade, substitution pattern, particle size, and supplier process can alter coating permeability. Talc concentration affects coating porosity and mechanical durability. Povidone can change drug distribution and water uptake. Magnesium stearate can delay wetting when over-lubrication occurs.

Lactose is commercially attractive because it is inexpensive and widely available, but it can create compatibility and moisture-management issues. A lactose-free formulation could differentiate the product for selected patients, but it would require new development work and would not automatically provide a clinical advantage.

What FDA requirements apply to an AMRIX generic?

An AMRIX generic would generally proceed through the ANDA pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. For an extended-release product, dissolution similarity alone is unlikely to be sufficient. Pharmacokinetic studies normally compare exposure metrics such as Cmax and AUC under fasting and fed conditions.

Key development requirements include:

• Same active ingredient and dosage form.
• Equivalent strength and route of administration.
• Comparable release characteristics.
• Fed and fasted bioequivalence.
• Evaluation of dose proportionality where required.
• Stability data supporting the proposed shelf life.
• Control of pellet size, coating weight, assay, content uniformity, and dissolution.
• Assessment of alcohol-induced dose dumping if relevant to the formulation.
• Labeling consistent with the reference product, subject to allowable ANDA differences.

The regulatory risk is higher than for an immediate-release cyclobenzaprine tablet because small manufacturing changes can affect in vivo exposure. Scale-up of fluid-bed coating, capsule filling, and pellet blending requires process validation and tight in-process controls.

When did AMRIX lose exclusivity and what is the generic status?

AMRIX’s core product exclusivity has largely expired. The product was approved in 2007, and generic extended-release cyclobenzaprine capsules entered the market after FDA approvals in the mid-2010s. Immediate-release cyclobenzaprine products have been generic for many years.

The reference product’s commercial position weakened as generic competition expanded. Teva later reported AMRIX among products affected by generic competition and portfolio changes. Current marketing status can differ between the FDA reference listing, individual generic approvals, and commercial availability. FDA Orange Book records should be used for current patent and exclusivity status. (FDA, 2024a; Teva Pharmaceutical Industries Ltd., 2017)

Exclusivity issue	Assessment
New chemical entity exclusivity	Expired
Core product protection	No longer a reliable barrier to generic entry
Generic entry	Established
Paragraph IV relevance	Primarily historical for early ANDA filings
Current opportunity	Formulation, manufacturing, supply, and market-positioning differentiation
Biosimilar risk	Not applicable because AMRIX is a small-molecule drug

What patents protect AMRIX?

AMRIX’s historical protection centered on controlled-release formulations and related product claims rather than on a new chemical entity. Patent coverage may have included extended-release cyclobenzaprine compositions, dosage forms, and methods of treatment. The commercial significance of those patents has declined because the principal exclusivity period has expired and generic products are available.

A current patent analysis should distinguish among:

• Patents listed in the FDA Orange Book.
• Unlisted formulation or process patents.
• Continuations and divisionals.
• Patent-term adjustment.
• Patent-term extension.
• Expired patents.
• Litigation settlements affecting launch dates.
• Patents covering later formulations rather than the original AMRIX product.

The absence of a currently blocking Orange Book patent does not eliminate risk from manufacturing or formulation patents. It does mean that a conventional ANDA pathway is commercially more practical than it would have been during the original AMRIX launch period.

Which companies are challenging or competing with AMRIX?

Competition comes from three groups:

Generic extended-release cyclobenzaprine manufacturers

Generic suppliers compete mainly on price, pharmacy coverage, manufacturing reliability, and wholesaler access. The principal commercial challenge is not proving basic chemical equivalence. It is maintaining consistent supply and achieving acceptable margins in a mature generic category.

Immediate-release cyclobenzaprine suppliers

Immediate-release tablets are a direct therapeutic substitute. They are generally cheaper and widely available, although they require more frequent dosing. A once-daily extended-release product can retain demand among patients and prescribers who value convenience.

Alternative muscle relaxants

Tizanidine, baclofen, methocarbamol, carisoprodol, and metaxalone compete for the same prescribing occasions. Their commercial positioning depends on sedation, abuse potential, dosing frequency, drug interactions, and payer preference.

What commercial opportunities exist for AMRIX excipient innovation?

The strongest opportunities are incremental rather than molecule-based.

1. Lower-cost generic extended-release capsules

A sponsor can use a conventional pellet system with widely available excipients and target a low-cost, reliable supply position. The value proposition is price, payer access, and consistent availability.

2. Lactose-free or simplified formulations

A lactose-free product could address selected excipient sensitivities and simplify supply. This is a limited niche unless supported by clear labeling and commercial differentiation.

3. Improved alcohol-resistant release

A formulation with stronger resistance to alcohol-induced release could provide a quality and safety advantage. It would require dedicated dissolution testing and likely additional regulatory justification.

4. Alternative capsule shells

Hypromellose capsules may support vegetarian positioning and reduce dependence on gelatin. The change can affect moisture transfer, shell brittleness, fill weight, and dissolution. It is feasible but requires full comparability work.

5. Abuse-deterrent or tamper-resistant positioning

Cyclobenzaprine is not generally positioned as a high-priority abuse-deterrence product. Investment in abuse-deterrent technology would therefore require a clear clinical, regulatory, or payer rationale.

6. Fixed-dose combinations

A combination with an analgesic or anti-inflammatory agent could improve convenience, but it would face clinical-development, labeling, dose-flexibility, and combination-product risks. The combination would not be a simple AMRIX generic.

7. Geographic licensing and contract manufacturing

The product can support regional licensing where extended-release cyclobenzaprine is approved but generic competition is limited. Contract manufacturing opportunities are strongest for firms with fluid-bed coating, multiparticulate blending, and controlled-release capsule capabilities.

How strong is the AMRIX patent estate today?

The current patent estate is commercially weak compared with an active branded product protected by unexpired composition and method-of-use patents. The main barriers are technical execution, bioequivalence, manufacturing scale, and generic price pressure.

Protection category	Current commercial strength
Active ingredient	Low
Original extended-release concept	Low after expiration
New formulation patent	Potentially meaningful if technically distinct
Manufacturing process patent	Moderate if difficult to design around
Method-of-use patent	Limited in a mature generic market
Trade secret manufacturing know-how	Potentially meaningful
Regulatory exclusivity	Expired or largely exhausted
Biosimilar barriers	Not applicable

A new patent strategy would need claims directed to a measurable technical result, such as a defined dissolution profile, reduced food effect, improved alcohol resistance, enhanced stability, or a specific multiparticulate architecture. Broad claims covering cyclobenzaprine extended release are unlikely to provide durable protection in the current market.

What generic launch risks exist?

The main launch risks are:

1. Failure to match the reference pharmacokinetic profile.
2. Food-effect differences.
3. Dose dumping under high alcohol exposure.
4. Pellet segregation during capsule filling.
5. Coating variability during scale-up.
6. Supply disruption for specialty polymers or capsule shells.
7. Price erosion after multiple ANDA approvals.
8. Substitution by low-cost immediate-release tablets.
9. Limited payer willingness to reimburse a premium formulation.
10. Inconsistent availability of the branded reference product for comparative studies.

Revenue exposure for the reference product is therefore structurally negative after generic entry. The opportunity shifts to high-volume, low-cost supply, niche reformulation, licensing, or a differentiated modified-release product.

How does AMRIX compare with immediate-release cyclobenzaprine?

Factor	AMRIX extended release	Immediate-release cyclobenzaprine
Dosing	Once daily	Usually multiple daily doses
Formulation complexity	High	Low
Bioequivalence burden	High	Lower
Manufacturing cost	Higher	Lower
Patient convenience	Higher	Lower
Generic competition	Established	Extensive
Patent opportunity	Incremental formulation claims	Limited
Commercial positioning	Convenience and adherence	Price and availability

Key Takeaways

• AMRIX is a multiparticulate extended-release cyclobenzaprine capsule, not a simple immediate-release product.
• The most important excipients are release-controlling polymers, pellet binders, coating aids, surfactants, and capsule-shell materials.
• AMRIX’s core exclusivity has expired, and generic competition is established.
• Biosimilar risk does not apply because cyclobenzaprine is a small molecule.
• The strongest current opportunities are low-cost generic supply, lactose-free or vegetarian formulations, improved alcohol resistance, and regional licensing.
• A new patent position must rely on a technically specific formulation or manufacturing improvement.
• The main development risk is failure to reproduce the reference product’s in vivo release profile under fed and fasted conditions.

FAQs

Is AMRIX still commercially available?

Availability varies by market and supplier. Generic extended-release cyclobenzaprine products are the principal commercial substitutes, while the branded product has had reduced commercial importance after generic entry.

Can AMRIX be reformulated as a tablet?

Yes, but a tablet would require separate development and bioequivalence work. A tablet matrix may not reproduce the reference capsule’s multiparticulate release behavior.

Which excipient is most important for AMRIX release?

The release-controlling polymer system is generally the most important variable. Polymer grade, coating weight, porosity, and pellet size can materially change dissolution and pharmacokinetics.

Does AMRIX have biosimilar competition?

No. Biosimilar regulation applies to biological products. Cyclobenzaprine is a chemically synthesized small-molecule drug, so competition proceeds through generic drug pathways.

Is a new AMRIX formulation patentable?

Potentially, if the formulation has a novel and non-obvious structure or produces a demonstrated technical benefit. Broad claims covering generic extended-release cyclobenzaprine are less likely to provide meaningful protection.

References

1. DailyMed. (2023). AMRIX: Cyclobenzaprine hydrochloride extended-release capsules prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2017a). AMRIX prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. Teva Pharmaceutical Industries Ltd. (2017). Annual report. Teva Pharmaceuticals.